Screener
Xenon Pharmaceuticals XENE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 99,224 | 74,985 | 187,732 | 136,185 |
| General and administrative | 23,931 | 19,244 | 47,751 | 38,282 |
| Total operating expenses | 123,155 | 94,229 | 235,483 | 174,467 |
| Loss from operations | (123,155) | (94,229) | (235,483) | (166,967) |
| Other income: | ||||
| Interest income | 12,145 | 7,199 | 19,052 | 15,282 |
| Foreign exchange gain (loss) | (311) | 1,698 | 237 | 1,733 |
| Total other income | 11,834 | 8,897 | 19,289 | 17,015 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's operating income?
- Xenon Pharmaceuticals (XENE) reported operating income of -$123.16M in Q2 2026.
- How has Xenon Pharmaceuticals's operating income changed year-over-year?
- Xenon Pharmaceuticals's operating income decreased by 30.7% year-over-year, from -$94.23M to -$123.16M.
- What is the long-term trend for Xenon Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's operating income has grown at a 47.4% compound annual growth rate (CAGR), from -$78.99M to -$373.07M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Xenon Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude